BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Endovasc Inc. (EVSC) Announces Formation of BioFlow, Inc.


6/4/2007 2:46:46 PM

MONTGOMERY, Texas--(BUSINESS WIRE)--Endovasc, Inc. (OTCBB:EVSC) is pleased to announce that it has created a new wholly owned subsidiary BioFlow, Inc. to manage the continued development of biodegradable stents. Endovasc, Inc. and Dr. Nathan Blumberg have jointly transferred the intellectual property from both of the previous Joint Ventures involving TissueGen Inc. into the new subsidiary BioFlow, Inc.

The first project is to develop a biodegradable urinary stent for ureteral application. Dr. Blumberg will continue to contribute his expertise to develop and ultimately commercialize novel biodegradable stents for ureteral applications. A unique product design conceived by Dr. Blumberg will be incorporated into the device. BioFlow, Inc. will manage product definition and the development process through a Sponsored Laboratory Research Agreement. The objective of this project is to develop biodegradable ureteral and urethral stents that can be degraded in the body within 7-14 days after a procedure. All intellectual property developed under this research agreement is assigned to BioFlow, Inc.

About Endovasc, Inc.

Endovasc, Inc. is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, and owns interests in three portfolio companies: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation.

For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor Statement

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.

Contacts

Endovasc, Inc. Dr. Diane Dottavio, 936-582-5920



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES